



March 20, 2025

The Manager
BSE Limited
Corporate Relationship Department
P. J. Towers, Dalal Street,
Mumbai – 400 001.

The Manager
The National Stock Exchange of India Limited Exchange
Plaza,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051.

BSE Scrip Code No. 524280

NSE Symbol: KOPRAN

Dear Sir/Madam,

Sub: Press Release

The Board in its meeting(s) held on March 20, 2025 has approved the Merger of Kopran Laboratories Limited (CIN: U24230MH1986PLC040602), a promoter group company with Kopran Limited (CIN: L24230MH1958PLC011078) (“Company”) subject to in principal approval from the Stock Exchange and Securities Exchange Board of India, shareholders and other regulatory approvals.

The proposed consideration for the Merger will be done as per the “Share Exchange Ratio”:

“**100 (One Hundred)** fully paid Equity Shares of **INR 10** each of Kopran Limited (Transferee Company) against **45 (Forty-Five)** Equity Share of **INR 10** of Kopran Laboratories Limited (Transferor Company) to each of the equity shareholder holding fully paid-up Equity Shares in the Transferor Company and whose name is recorded in the Register of Members of Transferor Company as on the record date.”

Brief Profile of Kopran Laboratories Ltd (KLL).

KLL operates in the fast-growing Indian diagnostics segment and is engaged in the business of marketing diagnostic equipment’s, consumables and automation solutions to pathlabs and hospitals.

KLL also provides equipment and other infrastructure to its customers by entering into long term agreements for consumable purchases and support services, thereby enabling them to upgrade their facilities without any capital investments.

It represents many multinational companies for marketing their products in India and has a Pan India team of sales and service.

KLL executes turnkey services for government hospitals and medical colleges to set up and automate their path labs.



KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078.
Works: • Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337 • Fax: (02192) 274025

Brief of Financials

Amount (Rs. in Lakhs)				
Kopran Laboratories Ltd.	Audited	Audited	Audited	Audited
Particulars (in Rs.)	FY 21-22	FY 22-23	FY 23-24	as on Dec 31,2024
Revenue from operation	5,386.88	7,056.96	10,240.47	6824.76
EBITDA	946.11	1,677.78	2825.97	1726.22
EBITDA %	17.56%	23.77%	27.60%	25.29%
Profit after tax	601.13	926.31	1,828.74	1132.09
PAT %	11.16%	13.13%	17.86%	16.59%

Note: As on December 31, 2024, KLL cash and cash equivalent (net of borrowings) amounts to Rs.2456.13 Lakhs

It is proposed to merge Kopran Ltd. and Kopran Laboratories Ltd. to leverage the strength of both the companies and create a synergy in exploiting the healthcare and diagnostic market.

- The merger will give Kopran entry in fast growing \$14 billion Indian Diagnostic Industry which is growing at a CAGR of 14% over the next 5 years and is expected to almost double and reach \$25 billion in FY 28 and nearly threefold by 2034 (source: The Hindu Business Line).
- The merger will allow Kopran to capitalize on KLL relationships and team for marketing Kopran's products into hospitals and government institutions.
- Kopran Ltd will leverage its manufacturing capabilities to repack and manufacture diagnostic kits thereby increasing margins and profitability.
- This will take Kopran one step further in becoming an integrated health care and pharma company.
- The merger will be EPS accretive to Kopran and create value for its shareholders.

Kindly disseminate the information on the Exchange website.

Regards,

For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer
Membership No. FCS 3897